Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus V CILLIN K.
BICILLIN vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic